17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro

被引：0
|
作者：
Korfee, S.
Gauler, T.
Nishio, K.
Arao, T.
Saijo, N.
Cortes-Incio, D.
Pottgen, C.
Krbek, T.
Seeber, S.
Eberhardt, W. E. E.
机构：
[1] West German Canc Ctr, Essen, Germany
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Natl Canc Ctr Hosp East, Chiba, Japan
[4] Ruhriandklinik, Essen, Germany
来源：
LUNG CANCER | 2006年 / 54卷
关键词：
D O I：
10.1016/S0169-5002(07)70298-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [31] Modulation of the HSP90 co-chaperone AHA1 affects client protein activity and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)
    Holmes, J.
    Sharp, S.
    Workman, P.
    EJC SUPPLEMENTS, 2006, 4 (12): : 183 - 183
  • [32] The HSP90 inhibitor, 17-AAG, stimulates in vitro and in vivoosteoclast formation and enhances bone metastasis in an animal model of humanbreast cancer metastasis
    不详
    CLINICAL & EXPERIMENTAL METASTASIS, 2004, 21 (07) : 640 - 640
  • [33] Targeting shock 90 protein (HSP90) by 17-allylamino-17-demethoxygeldanamycin (17-AAG) in acute leukemias
    Flandrin-Gresta, P.
    Tavernier, E.
    Manissolle, C.
    Guyotat, D.
    Campos, L.
    BULLETIN DU CANCER, 2008, 95 : S61 - S62
  • [34] Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX
    Powers, Marissa V.
    Valenti, Melanie
    Miranda, Susana
    Maloney, Alison
    Eccles, Suzanne A.
    Thomas, George
    Clarke, Paul A.
    Workman, Paul
    ONCOTARGET, 2013, 4 (11) : 1963 - 1975
  • [35] The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression
    Georgakis, Georglos V.
    Li, Yang
    Rassidakis, Georgios Z.
    Medeiros, L. Jeffrey
    Younes, Anas
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (12) : 1670 - 1679
  • [36] The Hsp90 inhibitor 17-AAG represses calcium-induced cytokeratin 1 and 10 expression in HaCaT keratinocytes
    Miyoshi, Sadanori
    Yamazaki, Shota
    Uchiumi, Asato
    Katagata, Yohtaro
    FEBS OPEN BIO, 2012, 2 : 47 - 50
  • [37] Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
    O'Malley, Katherine J.
    Langmann, Gabrielle
    Ai, Junkui
    Ramos-Garcia, Raquel
    Vessella, Robert L.
    Wang, Zhou
    PROSTATE, 2012, 72 (10): : 1117 - 1123
  • [38] Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?
    Mehta, Adi
    Shervington, Amal
    Howl, John
    Jones, Sarah
    Shervington, Leroy
    FEBS OPEN BIO, 2013, 3 : 271 - 278
  • [39] Synthesis and biological evaluation of IPI-504, an aqueous soluble analog of 17-AAG and potent inhibitor of Hsp90
    Porter, James R.
    Ge, Jie
    Normant, Emmanuel
    Ali, Janid
    Dembski, Marlene S.
    Gao, Yun
    Georges, Asimina T.
    Grenier, Louis
    Patterson, Jon
    Sydor, Jens R.
    Wright, Jim
    Adams, Julian
    Tong, Jeffrey K.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [40] TREATMENT OF LEUKEMIC CELLS WITH HSP90 INHIBITOR 17-AAG INDUCES G2/M ARREST AND APOPTOSIS
    Napper, J. M.
    Sollars, V. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 544 - 544
12345